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4-OH-Tamoxifen is not an agonist of the frog aryl hydrocarbon receptor 
Amanda Maxfield ’12 and Professor Wade Powell 
 Department of Biology, Kenyon College, Gambier, Ohio  
Abstract 
 The aryl hydrocarbon receptor (AHR) is a ligand activated transcription factor 
found in all vertebrates.  The AHR mediates toxicity of a wide range of xenobiotics, including 
such planar halogenated aromatic hydrocarbons as the classical agonist 2, 3, 7, 8-
tetrachlorodibenzo-p-dioxin (TCDD). 4-hydroxy-tamoxifen (4-OH-TAM) is an active metabolite 
of the selective estrogen receptor (SERM) tamoxifen. SERMS have been used to treat and 
prevent breast cancer connected with abnormal estrogen receptor (ER) signaling by estradiol 
in ERα positive breast cancers. Studies have shown that 4-OH-TAM regulates the activity of 
the AHR in MCF7 breast cancer cells. Along with other genes, CYP1A1 mRNAs were induced. 
This project sought to use low affinity AHRs from Xenopus laevis to test the hypothesis that 4-
OH-TAM is a classical agonist of the AHR.  Like TCDD, we expect 4-OH-TAM to induce frog 
CYP1A6 expression with a potency much lower than in mouse cells.    
 CYP1A mRNA induction by 4-OH-TAM was tested in dose-response studies in 
the XLK-WG frog cell line, and compared against induction in the Hepa1c1c7 mouse 
hepatoma line. CYP1A6 mRNA was not induced by 4-OH-TAM in the frog cells. Consistent 
with data from other groups, 4-OH-TAM was a weak inducer of CYP1A1 in the mouse cells. At 
5mM, it induced CYP1A1 ~6-fold over control, compared with >400-fold for 100 nM TCDD. 
This suggests that like many other compounds which induce CYP1A1 in mice, 4-OH-TAM is 
not an AHR agonist in X. laevis.   
t 
• The AHR is a ligand activated transcription factor which induces 
monooxygenase expression (CYP1A enzymes) in response to 
various exogenous and endogenous compounds.  
• The AHR has a role in the detoxification of xenobiotics such as 
the environmental contaminant TCDD.   
• AHR agonists, such as TCDD, upregulate CYP1A expression.  
• The AHR has a relatively promiscuous ligand-binding pocket [1]. 
Multiple metabolites of tamoxifen have been shown to act as 
AHR ligands in MC7 breast cancer cells [2]. 
• The AHR in X. laevis binds the canonical agonist TCDD with a 
much lower affinity than observed in other model systems.  
• The X. laevis AHR is relatively more responsive to some ligands, 
including the endogenous compound formylindolo[3,2-b]
carbazole (FICZ) [4].   
Figure 1.  Aryl hydrocarbon agonist 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin 
(TCDD) and selective estrogen receptor 4-hydroxy tamoxifen (4-OH-TAM).     
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•  4-OH-TAM (4OHT) is an active metabolite of the selective 
estrogen receptor (SERM) tamoxifen (TAM).   
•  SERMS have been used to treat and prevent breast cancer 
connected with abnormal estrogen receptor (ER) signaling by 
estradiol in ERα positive breast cancers [2].   
•  In breast tissue, SERMS compete with estrogen at the ER 
binding site.  Thus, SERMS function by starving tumor cells of 
the estrogen necessary for their survival and proliferation [3].  
•  The TAM metabolite 4OHT can act as both an agonist and 
antagonist depending on its location in differing cell types. 
•  Recently, it has been shown that multiple metabolites of TAM, 
including 4OHT, affect AHR signaling independently of ER [2].  
4-hydroxy tamoxifen 
• To determine if CYP1A6 mRNA’s are induced by 4-OH-TAM in XLK-WG 
cells.   
• To observe CYP1A mRNA induction by 4-OH-TAM in dose-dependent 
studies in XLK-WG and Hepa1c1c7 cells. 
Objective 
CYP1A mRNA induction 
Figures 2-3. XLK-WG were exposed to serial dilutions of 4-OH-TAM to examine 
the dose-dependency of mRNA induction. Mouse Hepa1c1c7 cells were used as 
a positive control so that the responsiveness of both X. laevis and mouse cells to  
4-OH-TAM could be compared. Induced CYP1A mRNA were quantified with real-
time PCR.    
CYP1A  i tion 
Figure 2. CYP1A1 
mRNA induction 
by 
 4-OH-TAM in 
XLK-WG cells  
Figure 3. CYP1A6  
mRNA induction by 
 4-OH-TAM in  
Hepa1c1c7 cells 




























Figures 4-5. Comparisons of CYP1A mRNA induction by 4-OH-TAM in  
XLK-WG and Hepa1c1c7 cells.    
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 Conclusion 
 4-OH-TAM is a weak inducer of CYP1A1 in mouse cells, 
inducing only ~6-fold over control at 5mM. CYP1A1 induction 
by TCDD was >400-fold over control at 100 nM TCDD.  
  4-OH-TAM is not an AHR agonist in frog cells. 
  At certain concentrations, 4-OH-TAM may actually inhibit 
CYP1A mRNA induction compared to control in frog cells. 
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Figure 4. Comparison of 
highest fold CYP1A mRNA 
induction by 4-OH-TAM in 
XLK-WG and Hepa1c1c7 
cells 
Figure 5. Comparison of  
CYP1A mRNA induction 
for all trials by 4-OH-TAM 
in XLK-WG and 
Hepa1c1c7 cells  
0.0001 0.001 0.01 0.1 1 10
0
10
20
XLK-WG
Hepa1c1c7
XLK-WG TCDD
300
400
0
Hepa1c1c7 TCDD
log [4OHTAM] µM
